Bluebird bio Takes Hit with FDA Clinical Hold on Gene Therapy

Submitted by admin on August 9, 2021 - 11:48pm

Source:

BioSpace

News Tags:

Bluebird Bio

FDA

clinical hold

gene therapy

eli-cel

cerebral adrenoleukodystrophy

Headline:

Bluebird bio Takes Hit with FDA Clinical Hold on Gene Therapy

snippet:

Shares of bluebird bio were down more than 24% after the company announced that the U.S. Food and Drug Administration placed a clinical hold on studies of its elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD).

Search form

You are here

Bluebird bio Takes Hit with FDA Clinical Hold on Gene Therapy

Bluebird bio Takes Hit with FDA Clinical Hold on Gene Therapy